Professor Tara Spires-Jones, President of the British Neuroscience Association, UK Dementia Research Institute Group Leader, and Deputy Director of the Centre for Discovery Brain Sciences at the University of Edinburgh, shared her perspective on Elon Musk's announcement that Neuralink has successfully implanted a wireless brain chip in a human. She emphasized that the concept of brain-machine interfaces, such as Neuralink, has been a topic of interest for both companies and academic scientists. These interfaces hold significant potential to aid individuals with neurological disorders, showcasing the translation of fundamental neuroscience research into medical advancements.


While acknowledging the strides made in recent research trials—unrelated to Neuralink—Professor Spires-Jones pointed out the successful implantation of brain-spine interfaces benefiting those with paralysis, enabling them to walk. Additionally, advancements in interpreting brain waves and scans have shown promise in creating interfaces that allow non-verbal individuals to communicate through computers. However, she emphasized that many of these interfaces currently necessitate invasive neurosurgery and remain in the experimental stages. As a result, widespread availability of such technologies is expected to take several years before becoming commonplace.

Professor Anne Vanhoestenberghe, who holds the position of Professor of Active Implantable Medical Devices at King’s College London, provided insights into the significance of Neuralink's announcement regarding the successful implantation of a wireless brain chip in a human. According to her, achieving the milestone of the first human test is a noteworthy accomplishment for any company involved in the production of medical devices. Within the brain-computer interface (BCI) community, this development takes on added importance, considering that only a select few companies have ventured into human implantation, placing Neuralink in a relatively small group within this field.





Regarding the timeline for determining the success of the procedure, Professor Vanhoestenberghe speculated that Neuralink might allow the participant time to recover before initiating training with the system. Acknowledging Elon Musk's proclivity for generating publicity for his company, she anticipated potential announcements once testing commences. However, she emphasized that the true measure of success should be evaluated over the long term, considering the stability of the interface over time and the benefits experienced by the participant.

When questioned about the safety of the procedure, Professor Vanhoestenberghe remarked that there is insufficient information available at present. In her closing comments, she highlighted Neuralink's role in bringing attention to a small yet dynamic field. While acknowledging the commendable achievements of a few companies already using similar devices in humans and the remarkable progress made by the neuroscience community, she emphasized that the potential benefits of such interfaces are still constrained by existing technology. She stressed the need for more investments and time to develop and validate core technology for long-term use in humans, underscoring the importance of ongoing work to support the evolution of the next generation of BCIs and other active implants.